No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 24
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:02:02.472Z. Latest historical point 2026-05-07. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for ImageneBio Inc (IMA) stock was $4.70 as of Oct 6, 2026, 10:00 AM EDT, unchanged from the previous close.
Longer view (total return, dividends reinvested): past 12 months -45.2% · 3-year avg -54.6%/yr · 5-year avg -50.7%/yr
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Biotechnology · San Diego, CA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.83
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.63
vs Estimate
$-0.98
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1IMA | $53.01M | $4.70 | +0.00% | -45.19% | -50.73% | N/A | N/A |
| 2ELOX | $53.23M | $15.49 | +0.52% | N/A | N/A | N/A | vs IMA |
| 3DWTX | $52.46M | $1.56 | +2.63% | -76.12% | -58.44% | N/A | vs IMA |
| 4BTMD | $51.61M | $1.17 | +4.47% | -62.24% | -35.12% | N/A | vs IMA |
| 5EXOZ | $51.51M | $5.55 | +0.54% | -58.32% | N/A | N/A | vs IMA |
| 6MBOT | $51.27M | $1.13 | +5.14% | -64.98% | -31.63% | -39.57% | vs IMA |
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$18.00
+283.0% upside
Low
$2.00
Current
$4.70
High
$28.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.95 | $-0.80 | $-0.66 | 3 |
| Quarter ending Dec 2026 | $-1.01 | $-0.91 | $-0.76 | 3 |
| Quarter ending Mar 2027 | $-0.79 | $-0.79 | $-0.79 | 1 |
| Quarter ending Jun 2027 | $-0.84 | $-0.84 | $-0.84 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.56 | $-3.22 | $-2.94 | 3 |
| FY 2027 | $-5.24 | $-3.48 | $-0.94 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $340244.00 | $340244.00 | $340244.00 | 4 |
| FY 2027 | $144707.00 | $144707.00 | $144707.00 | 4 |
